Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Nifedipine

FDA-approved product (capsule, oral), marketed as Adalat, Adalat Cc, Afeditab Cr and 3 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Nifedipine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Coronary Vasospasm
  • Hypertension

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Dihydropyridine derivatives
FDA pharmacologic class
Dihydropyridine Calcium Channel Blocker FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA46.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli32.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae12.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis55.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Nifedipine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Nifedipine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Effects of Adalat LA and Coracten on Drug Levels, Blood Pressure, and Heart Rate in Fed Patients With Hypertension

    NCT00672113 · start 2003-12

    Registered record
    Registry ID
    NCT00672113
    Conditions
    Hypertension
    Interventions
    Adalat (Nifedipine, BAYA1040); Coracten
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-12
    Completion
    2004-08
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionAdalat (Nifedipine, BAYA1040); Coracten
    PhasePhase 4
    Registry statusCompleted

  • Treatment of Supine Hypertension in Autonomic Failure

    NCT00223717 · start 2001-01

    Registered record
    Registry ID
    NCT00223717
    Conditions
    Hypertension
    Interventions
    Clonidine; Nitroglycerin transdermal; Dipyridamole/ Aspirin (Aggrenox); Desmopressin (DDAVP); Sildenafil; Nifedipine; Hydralazine; Hydrochlorothiazide; Placebo; Bosentan; Diltiazem; Eplerenone; guanfacine; L-arginine; captopril; carbidopa; losartan; metoprolol tartrate; nebivolol hydrochloride; prazosin hydrochloride; tamsulosin hydrochloride; Head-up tilt.; aliskiren; Local heat stress
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2001-01
    Completion
    2017-01
    Enrolment
    152

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionClonidine; Nitroglycerin transdermal; Dipyridamole/ Aspirin (Aggrenox); Desmopressin (DDAVP) +20 more
    PhasePhase 1
    Registry statusCompleted

  • Magnesium Sulfate Versus Nifedipine for the Acute Tocolysis of Preterm Labor: A Prospective, Randomized Trial

    NCT00185900 · start 1999-04

    Registered record
    Registry ID
    NCT00185900
    Conditions
    Obstetric Labor, Premature
    Interventions
    Magnesium Sulfate; Nifedipine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    1999-04
    Completion
    2007-07
    Enrolment
    192

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObstetric Labor, Premature
    InterventionMagnesium Sulfate; Nifedipine
    PhaseNot applicable
    Registry statusCompleted

  • Drugs for High Blood Pressure and High Cholesterol in American Indians With Type 2 Diabetes

    NCT00004266 · start 1993-08

    Registered record
    Registry ID
    NCT00004266
    Conditions
    Diabetic Nephropathy
    Interventions
    Lisinopril; Nifedipine; Simvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1993-08
    Completion
    1999-07
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetic Nephropathy
    InterventionLisinopril; Nifedipine; Simvastatin
    PhasePhase 3
    Registry statusCompleted

  • A Study of Nifecardia SRFC and Adalat OROS in the Treatment of Patients With Essential Hypertension

    NCT00173667

    Registered record
    Registry ID
    NCT00173667
    Conditions
    Hypertension
    Interventions
    Nifedipine 30 mg GITS
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionNifedipine 30 mg GITS
    PhasePhase 4
    Registry statusUnknown